VivoSeq
Infectious Disease

Chronic Hepatitis

483

Pipeline Programs↗

74

Active Trials↗

112

Companies Involved↗

Chronic Hepatitis is a highly competitive landscape with 483 programs across 112 companies. The most active players are Inovio Pharmaceuticals, Peregrine Pharmaceuticals, Nanogen Pharmaceutical Biotechnology Joint Stock Company. 90 therapies are approved with 98 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

94/100

Pipeline Velocity

47/100

Mech. Concentration

7/100

Completion Rate

85/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Inovio Pharmaceuticals logo

Inovio Pharmaceuticals

2 programs

Phase 1P

Peregrine Pharmaceuticals

1 program

Phase 1N

Nanogen Pharmaceutical Biotechnology Joint Stock Company

1 program

Phase 1F

Fujian Shengdi Pharmaceutical Co., Ltd.

1 program

Phase 1E

Epigenic Therapeutics, Inc

1 program

Phase 1T

TetraLogic Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

96%

Small molecule

558 of 580 classified programs — the dominant modality here.

4%ALL OTHERSVaccine112%Protein / enzyme3<1%RNA therapy3<1%Monoclonal antibody2<1%Peptide2<1%Cell therapy1<1%

Small molecule leads; the ring shows all 580 classified programs, each share of the total. Modality classified for 100% of 625 pipeline programs.

Analysis

Trial Status

985

clinical trials

Completed638 · 65%
Unknown status151 · 15%
Terminated83 · 8%
Withdrawn33 · 3%
Recruiting30 · 3%
Active, not recruiting26 · 3%
Other24 · 2%

Clinical Trials

Trial Activity

985 trials

HepB mAb19 in Individuals With Chronic Hepatitis B Infection
Recruiting·RRockefeller University·Phase 1·NCT05856890·37 enrolled
Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon
Recruiting·—·N/A·NCT06696664·120 enrolled
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT06092333·50 enrolled
A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B
Recruiting·—·Phase 3·NCT07307586·120 enrolled
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
Recruiting·PPrecision BioSciences, Inc.·Phase 1·NCT06680232·45 enrolled
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B
Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT06566248·90 enrolled
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
Recruiting·—·Phase 4·NCT05140941·100 enrolled
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06154278·10 enrolled
Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients
Recruiting·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT05182463·5,000 enrolled
To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment
Recruiting·FFujian Akeylink Biotechnology Co., Ltd.·Phase 3·NCT07090759·526 enrolled
Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]
Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06216470·15 enrolled
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Recruiting·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·N/A·NCT06122285·100 enrolled
Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B
Recruiting·TTaichung Veterans General Hospital·N/A·NCT05583006·60 enrolled
Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B
Recruiting·—·Phase 1·NCT05922306·1,084 enrolled
Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B
Recruiting·PPeking University People's Hospital·Phase 1·NCT07328711·132 enrolled
Page 1 of 66

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)